Full Breakdown
Ocular Therapeutix's Axpaxli Shows Promise Against Regeneron's Eylea in Wet AMD
2/17/2026, 11:21:21 PM
Clinical Trial Results Highlight Axpaxli's Efficacy
Ocular Therapeutix announced promising results from its Phase 3 clinical trial of Axpaxli, an investigational treatment for wet age-related macular degeneration (AMD). The trial, known as SOL-1, demonstrated that 74% of participants receiving Axpaxli maintained their vision for nine months, compared to 56% of those treated with Regeneron’s Eylea. At one year, the figures were 66% for Axpaxli versus 44% for Eylea. These results indicate that Axpaxli may offer a less frequent injection schedule while achieving comparable visual acuity outcomes.
Study Design and Statistical Significance
The SOL-1 study involved 344 newly diagnosed wet AMD patients who had previously shown peak responses to Eylea injections. The primary endpoint was the proportion of participants maintaining visual acuity, defined as a loss of fewer than 15 letters on a vision test at week 36. Axpaxli achieved a statistically significant superiority over Eylea, with a risk difference of 17.5%. However, the narrower-than-expected difference in treatment durability has raised concerns among investors, leading to a 25% drop in Ocular's stock following the announcement.
Market Implications and Analyst Perspectives
William Blair analysts noted that while the results may not have met investor expectations, the market reaction was "unwarranted." They emphasized that the control arm's performance exceeded expectations rather than Axpaxli's underperformance. Ocular's Chief Medical Officer, Nadia Waheed, expressed confidence in the ongoing SOL-R study, which is designed to assess Axpaxli's effectiveness in a more stable patient population. The data from SOL-1 will support a new drug application with the FDA, with results expected to be presented at an upcoming medical meeting.
Competitive Landscape and Future Directions
Regeneron's Eylea remains a dominant player in the wet AMD market, generating $2.75 billion in sales in 2025. The company is also expanding its product line with a high-dose version of Eylea that allows for extended dosing intervals. Ocular Therapeutix, which previously collaborated with Regeneron on a sustained-release version of Eylea, is now focusing on Axpaxli and exploring its potential in diabetic retinal diseases. The company also markets Dextenza, a monthly insert approved in 2021 for treating allergic conjunctivitis.
Criticism and Concerns
Despite the positive trial results, some analysts and investors remain skeptical about Axpaxli's commercial viability in a market already saturated with effective treatments. The narrower efficacy margins compared to Eylea could hinder Axpaxli's acceptance among healthcare providers and patients.
Verbatim Quotes
- “We nonetheless believe these are positive results, as the compression in effect size was driven by the control arm outperforming expectations rather than Axpaxli underperforming,” — William Blair Analysts
Ocular Therapeutix's Axpaxli presents a potential new option for patients with wet AMD, but its future in a competitive landscape remains uncertain as the company prepares for further studies and regulatory discussions.
